Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 2, 2012, Pages 318-323

  Park, Hye Yoon ^a   Lee, Byoung Jo ^a   Kim, Jong Hoon ^b   Bae, Jae Nam ^c   Hahm, Bong Jin ^a,d  

^a Seoul National University Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Antidepressant; Breast cancer; Depression; Escitalopram; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; ESCITALOPRAM; ZOLPIDEM;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DISTRESS SYNDROME; DISTRESS THERMOMETER; DROWSINESS; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST; HAMILTON SCALE; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR CLINICAL STUDY; MD ANDERSON SYMPTOMS INVENTORY; NAUSEA AND VOMITING; OPEN STUDY; OUTPATIENT; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT OUTCOME; WELLBEING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TIME FACTORS;

EID: 84855358403     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.11.010     Document Type: Article

References (36)

1. American Psychiatric Association A.P. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC.
2. Brady M.J., Cella D.F., Mo F., Bonomi A.E., Tulsky D.S., Lloyd S.R., Deasy S., Cobleigh M., Shiomoto G. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. Journal of Clinical Oncology 1997, 15:974-986.
3. Bray F., McCarron P., Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Research 2004, 6:229-239.
4. Burke W.J., Gergel I., Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. The Journal of Clinical Psychiatry 2002, 63:331-336.
5. Cleeland C.S., Mendoza T.R., Wang X.S., Chou C., Harle M.T., Morrissey M., Engstrom M.C. Assessing symptom distress in cancer patients - The M. D. Anderson Symptom Inventory. Cancer 2000, 89:1634-1646.
6. Colonna L., Andersen H.F., Reines E.H. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Current Medical Research and Opinion 2005, 21:1659-1668.
7. Costa D., Mogos I., Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica 1985, 72:85-92.
8. Deshields T., Tibbs T., Fan M.Y., Taylor M. Differences in patterns of depression after treatment for breast cancer. Psycho-Oncology 2006, 15:398-406.
9. Fann J.R., Thomas-Rich A.M., Katon W.J., Cowley D., Pepping M., McGregor B.A., Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. General Hospital Psychiatry 2008, 30:112-126.
10. Fisch M.J., Loehrer P.J., Kristeller J., Passik S., Jung S.H., Shen J.Z., Arquette M.A., Brames M.J., Einhorn L.H. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology 2003, 21:1937-1943.
11. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Weinshilboum R.M., Fritcher E.G.B., Nibbe A.M., Desta Z., Nguyen A., Flockhart D.A., Perez E.A., Ingle J.N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment 2007, 101:113-121.
12. Grassi L., Biancosino B., Marmai L., Righi R. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. The Journal of Clinical Psychiatry 2004, 65:515-520.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology-revised 1976, National Institute of Mental Health, (US Department of Health, Education, and Welfare No ADM 76-338).
14. Haghighat S., Akbari M.E., Holakouei K., Rahimi A., Montazeri A. Factors predicting fatigue in breast cancer patients. Supportive Care in Cancer 2003, 11:533-538.
15. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
16. Henry N.L., Stearns V., Flockhart D.A., Hayes D.F., Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. The American Journal of Psychiatry 2008, 165:1251-1255.
17. Hjerl K., Andersen E.W., Keiding N., Mouridsen H.T., Mortensen P.B., Jorgensen T. Depression as a prognostic factor for breast cancer mortality. Psychosomatics 2003, 44:24-30.
18. Kasper S., Baldwin D.S., Lonn S.L., Boulenger J.P. Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology 2009, 19:229-237.
19. Lepola U.M., Loft H., Reines E.H. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo controlled study in depression in primary care. International Clinical Psychopharmacology 2003, 18:211-217.
20. Montgomery S.A., Huusom A.K.T., Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004, 50:57-64.
21. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L.R., Flynn P.J., Hynes H.E., Banerjee T.K., Kirshner J.J., King D.K. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology 2003, 21:4635-4641.
22. Murdoch D., Keam S.J. Escitalopram - a review of its use in the management of major depressive disorder. Drugs 2005, 65:2379-2404.
23. Musselman D.L., Somerset W.I., Guo Y., Manatunga A.K., Porter M., Penna S., Lewison B., Goodkin R., Lawson K., Lawson D., Evans D.L., Nemeroff C.B. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. The Journal of Clinical Psychiatry 2006, 67:288-296.
24. National Comprehensive Cancer Network Distress management. Clinical practice guidelines. Journal of the National Comprehensive Cancer Network 2003, 1:344-374.
25. Nierenberg A.A., Greist J.H., Mallinckrodt C.H., Prakash A., Sambunaris A., Tollefson G.D., Wohlreich M.M. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current Medical Research and Opinion 2007, 23:401-416.
26. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982, 5:649-655.
27. Pinto-Meza A., Usall J., Serrano-Blanco A., Suarez D., Haro J.M. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference?. Journal of Affective Disorders 2006, 93:53-60.
28. Rao N. The clinical pharmacokinetics of escitalopram. Clinical Pharmacokinetics 2007, 46:281-290.
29. Roscoe J.A., Morrow G.R., Hickok J.T., Mustian K.M., Griggs J.J., Matteson S.E., Bushunow P., Qazi R., Smith B. Effect of paroxetine hydrochloride (Paxil(R)) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment 2005, 89:243-249.
30. Roth A.J., Kornblith A.B., Batel-Copel L., Peabody E., Scher H.I., Holland J.C. Rapid screening for psychologic distress in men with prostate carcinoma - a pilot study. Cancer 1998, 82:1904-1908.
31. Soares C.N., Thase M.E., Clayton A., Guico-Pabia C.J., Focht K., Jiang Q., Kornstein S.G., Ninan P., Kane C.P., Cohen L.S. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010, 17:700-711.
32. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biological Psychiatry 2003, 54:269-282.
33. Thase M.E., Entsuah R., Cantillon M., Kornstein S.G. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. Journal of Women's Health 2005, 14:609-616.
34. vanHeeringen K., Zivkov M. Pharmacological treatment of depression in cancer patients - a placebo-controlled study of mianserin. The British Journal of Psychiatry 1996, 169:440-443.
35. Ventura D., Armstrong E.P., Skrepnek G.H., Erder M.H. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current Medical Research and Opinion 2007, 23:245-250.
36. Wade A., Lemming O.M., Hedegaard K.B. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 2002, 17:95-102.